ClinicalTrials.gg
Active, not recruitingNCT07881705TRACERUpdated Oct 19, 2026

A Phase III, Randomized, Double-blind, Multi-center Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung Cancer

A Phase 3 interventional study of Trilaciclib and Trilaciclib Placebo in Myelosuppression, sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Jiangsu Simcere Pharmaceutical Co., Ltd. (part of Simcere Pharmaceutical Group Limited) · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jun 2026, registered Oct 2026).
Updated Oct 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 365 studies in Small Cell Lung Carcinoma with a site in China — 183 open to participants now, 215 under way, 36 of them phase 3. Small Cell Lung Carcinoma · China.

Enrollment
125th of 333
106 · median 63
Started
2026
with 48 others
Phase 3
57 of 365
23 open now
Primary completion
2027-07
later than 110 of 214 live
Registered
361st of 365
by date

Among the 365 studies in Small Cell Lung Carcinoma with a site in China, this one is the 125th largest by enrollment of the 333 interventional ones that give a count, is one of 49 that started in 2026, is one of 57 in phase 3, reaches primary completion later than 110 of the 214 other live ones, and was the 361st registered.

Small Cell Lung Carcinoma

1,302 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

183 of the 365 studies in Small Cell Lung Carcinoma with a site in China are open now. Recruiting first, the newest first:

178 more — sign in →

All 183 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 365 studies in Small Cell Lung Carcinoma with a site in China, or all of them as a file.
02

Study summary

The primary goal of this study is to evaluate the myelo-protective effect and safety of Trilaciclib in participants with limited stage small cell lung cancer (LS-SCLC) who are receiving concurrent chemo-radiotherapy.

Researchers will compare Trilaciclib with placebo (a look-alike substance that contains no drug) to see if Trilaciclib works better in protecting the participant's marrow function while receiving concurrent chemo-radiotherapy.

Read the detailed description

The study will enroll approximately 106 participants with LS-CLC. The participants will be randomly assigned in a 1:1 ratio to two groups. One group will receive treatment with Trilaciclib + concurrent chemo-radiotherapy. The other group will receive placebo + concurrent chemo-radiotherapy.

Participants will receive the investigational drug until completion of 4 cycles of Trilaciclib +chemotherapy and concurrent radiotherapy, occurrence of radiographic disease progression, intolerable toxicity, investigator-assessed lack of clinical benefit, voluntary withdrawal from study treatment by the participant or their legally authorized representative, pregnancy, lost to follow-up, death, or study termination, whichever occurs first.

The study process includes screening period, treatment period, end-of-treatment visit, safety follow-up visit, and end-of-study visit.

03

Conditions studied

  • Myelosuppression

Keywords

  • LS-SCLC
  • small cell lung cancer
  • Myelosuppression
  • Trilaciclib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. and/or cytologically confirmed small cell lung cancer (SCLC) with clinical staging confirming limited-stage disease and no evidence of distant ;
  • 2. Fit for concurrent chemo-radiotherapy;
  • 3. Adverse reactions related to prior anti-tumor surgery have fully recovered;
  • 4. Has at least one per 1.1 that has not been previously irradiated;
  • 5. (ECOG)performance status of 0 or 1;
  • 6. Has adequate organ and bone marrow function, without receipt of hematopoietic growth factors, blood transfusions, or transfusions within 14 days prior to the first dose of study drug;

Exclusion criteria

Exclusion Criteria:

  • 1. Extensive-stage small cell lung cancer
  • 2. mixed-type small cell lung cancer, and transformed small cell lung cancer;
  • 3. Has received prior anti-tumor therapy for small cell lung cancer, including radiotherapy, chemotherapy, or immunotherapy;
  • 4. Has known allergy to any study drug or its components, or has any to any study drug.
  • 5. Has any active infections requiring for intravenous treatment within 14 days prior to the first dose of study treatment;
  • 6. Has received any within 28 days prior to the first dose of study drug.
  • 7. Has received any major surgeries within 28 days prior to the first dose of study treatment or expects to receive major surgeries during the study;
  • 8. History of another active within the past 5 years, except for localized cancers that have been cured and are considered by the investigator to be at low risk of recurrence, including basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast.
  • 9. With a history of active tuberculosis infection within 1 year; trial participants with a history of active tuberculosis may be eligible for enrollment if, in the investigator's judgment, there has been no evidence of active tuberculosis for more than 1 year prior to the first dose.
  • 10. Active or chronic or infection;
  • 11. Known (HIV) infection or acquired immunodeficiency syndrome (AIDS).
  • 12. With cardiovascular disease within 6 months prior to the first dose
  • 13. History of interstitial lung disease/non-infectious pneumonitis requiring treatment, or current interstitial lung disease/non-infectious pneumonitis requiring steroid treatment;
  • 14. Prior or autologous hematopoietic stem cell transplantation or history of ;
  • 15. Pregnant or breastfeeding female trial participants, or female trial participants of . Female participants of childbearing potential may be enrolled if they have a negative blood pregnancy test within 7 days prior to the first dose and agree to use effective from the time of signing the form until 6 months after the last dose of study medication or the last radiotherapy, whichever is longer.
  • 16. Any other conditions that, in the investigator's opinion, make the participant unsuitable for enrollment.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    Trilaciclib + concurrent chemo-radiotherapy

    Drug: Trilaciclib at 240mg/m\^2 on Day 1, Day 2, Day 3 of each cycle before chemotherapy, for 4 cycles (21 days as 1 cycle). Etoposide Injection: 100 mg/m\^2, Day 1, Day 2, Day 3 of each cycle, for 4 cycles (21 days as 1 cycle). Carboplatin or Cisplatin Injection: on Day 1 of each cycle, for 4 cycles (21 days as 1 cycle); use Calvert formula to calculate Carboplatin dosage (AUC=5 mg/mL/min,750 mg at most); Cisplatin dosage is 75 mg/m\^2. Initiate QD (once daily) or BID (twice a day) radiotherapy during Cycle 2 of radiotherapy.

    Drug: Trilaciclib · Drug: Etoposide Injection · Drug: Carboplatin or Cisplatin Injection · Radiation: Radiotherapy

  • Placebo comparator
    Placebo+ concurrent chemo-radiotherapy

    Drug: Trilaciclib placebo on Day 1, Day 2, Day 3 of each cycle before chemotherapy, for 4 cycles (21 days as 1 cycle). Etoposide Injection: 100 mg/m\^2, Day 1, Day 2, Day 3 of each cycle, for 4 cycles (21 days as 1 cycle). Carboplatin or Cisplatin Injection: on Day 1 of each cycle, for 4 cycles (21 days as 1 cycle); use Calvert formula to calculate Carboplatin dosage (AUC=5 mg/mL/min,750 mg at most); Cisplatin dosage is 75 mg/m\^2. Initiate QD (once daily) or BID (twice a day) radiotherapy during Cycle 2 of radiotherapy.

    Other: Trilaciclib Placebo · Drug: Etoposide Injection · Drug: Carboplatin or Cisplatin Injection · Radiation: Radiotherapy

Interventions

  • Trilaciclib at 240mg/m\^2;

    Also known as: Cosela

  • OtherTrilaciclib Placebo

    250 mL of 5% dextrose in water or normal saline (0.9% sodium chloride solution)

  • Etoposide Injection at dose level of 100 mg/m\^2

  • DrugCarboplatin or Cisplatin Injection

    Use Calvert formula to calculate Carboplatin dosage (AUC=5 mg/mL/min,750 mg at most); Cisplatin at a dose level of 75 mg/m\^2.

  • RadiationRadiotherapy

    30-33 days of totally 60-66 Gy for QD radiation, or 15 days of totally 45 Gy for BID radiation.

06

What researchers measure

Primary outcomes

  1. The duration of severe neutropenia (DSN) in cycle 1

    The time duration of absolute neutrophil count (ANC) decrease meeting Grade 4 per NCI CTCAE 5.0 (i.e., ANC \< 0.5 × 10⁹/L).

    Time frame: During the first cycle (each cycle is 21 days)

  2. The incidence of severe neutropenia (SN)

    The incidence of absolute neutrophil count (ANC) decrease meeting Grade 4 per NCI CTCAE 5.0 (i.e., ANC \< 0.5 × 10⁹/L).

    Time frame: From the time of first dosing until 30 days after the end of study treatment, up to about 3.5 months

Secondary outcomes

  1. Granulocyte colony-stimulating factor (G-CSF) utilization rate

    Time frame: From the time of first dosing until 30 days after the end of study treatment, up to about 3.5 months

  2. Incidence of febrile neutropenia

    Time frame: From the time of first dosing until 30 days after the end of study treatment, up to about 3.5 months

  3. The lowest absolute neutrophil count in each cycle

    Time frame: From the time of first dosing until 30 days after the end of study treatment, up to about 3.5 months]

  4. Incidence of grade ≥3 hemoglobin decrease

    Time frame: From the time of first dosing until 30 days after the end of study treatment, up to about 3.5 month

  5. Incidence of red blood cell transfusions (from Week 5 onward)

    Time frame: From Week 5 until 30 days after the end of study treatment, up to about 3 months

  6. Erythropoiesis-stimulating agent (ESA) utilization rate

    Time frame: From the time of first dosing until 30 days after the end of study treatment, up to about 3.5 months

  7. Incidence of grade ≥3 platelet count decrease

    Time frame: From the time of first dosing until 30 days after the end of study treatment, up to about 3.5 months

  8. Incidence of platelet transfusions

    Time frame: From the time of first dosing until 30 days after the end of study treatment, up to about 3.5 months.

  9. Rate of thrombopoiesis-stimulating agent use.

    Time frame: From the time of first dosing until 30 days after the end of study treatment, up to about 3.5 months

  10. Incidence of grade 3 and 4 hematologic toxicities

    Time frame: From the time of first dosing until 30 days after the end of study treatment, up to about 3.5 months

  11. Changes over time in absolute neutrophil count, platelet count, absolute lymphocyte count, and hemoglobin

    Time frame: From the time of first dosing until 30 days after the end of study treatment, up to about 3.5 months

  12. Composite endpoint: Incidence of important hematologic adverse events.

    The proportion of patients who experience any of the following: hematologic adverse event that leads to hospitalization or prolongation of hospitalization, dose adjustment of chemotherapy, febrile neutropenia, prolongation of severe neutropenia(SN) (more than 5 days),or red blood cell (RBC) transfusions administered at or after Week 5.

    Time frame: From the time of first dosing until 30 days after the end of study treatment, up to about 3.5 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jul 2027, 12 months after the start.

Of 55 industry-sponsored phase 3 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 44. This study's planned 12 months is below that.

Counting every sponsor, half of 68 studies reached it within 41 months; a quarter within 31 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2026
First posted
Oct 19, 2026
StartActual
Jun 17, 2026
Primary completionEst.
Jul 15, 2027
CompletionEst.
Sep 30, 2027
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07881705
Collaborators
Simcere Zaiming Pharmaceutical Co., Ltd .
Responsible party
Sponsor
First posted
Oct 19, 2026
Start date
Jun 17, 2026
Primary completion
Jul 15, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Oct 19, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trilaciclib

Start the discussion